ClinicalTrials.gg
RecruitingNCT04846959Updated Jul 17, 2025

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

An observational study in Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment, sponsored by AbbVie. Recruiting at 2 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
818
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Planned enrollment
7th of 22
818 · median 474
Started
2021
with 2 others
Observational
22 of 34
2 open now
Registered
30th of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 7th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2021, is one of 22 observational ones, and was the 30th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and unexposed populations.

Approximately 818 female participants with pregnancy will be enrolled (409 participants exposed to risankizumab and 409 without exposure) at multiple sites across the United States.

Participants will not receive risankizumab as part of this study. Maternal and fetal outcomes during pregnancy for female participants who received risankizumab or other treatment will be followed for and up to 1 year after delivery

There may be a higher burden for participants in this study compared to standard of care. Participants will attend visits determined by HCPs during the study at a hospital or clinic. The pregnancy outcomes including side effects will be collected during routine clinical care.

03

Conditions studied

  • Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Keywords

  • Pregnancy
  • Risankizumab
  • SKYRIZI™
  • risankizumab-rzaa
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will comprise 2 cohorts of pregnant women.

  • One cohort will include pregnant women of any age in the US who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and exposed to risankizumab at any time during pregnancy .
  • The second cohort will include pregnant women of any age in the US who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and not exposed to risankizumab but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Risankizumab-Exposed Cohort

  • US resident.
  • Current pregnancy.
  • Diagnosis of plaque psoriasis, PsA, CD, or other condition(s) for which Risankizumab is an FDA-approved treatment while the study is recruiting.
  • Exposure to risankizumab at any time during pregnancy (at least 1 dose during pregnancy or within 20 weeks prior to conception).

Diseased Comparison Cohort

  • US resident.
  • Current pregnancy.
  • Diagnosis of plaque psoriasis, PsA, CD, or other condition(s) for which Risankizumab is an FDA-approved treatment while the study is recruiting.
  • Exposure to other medications in the same class or as risankizumab (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitor, and other IL-23 inhibitors) at any time during pregnancy (at least 1 dose during pregnancy or prior to pregnancy within a specified time period based on the product's half-life).

Exclusion criteria

Exclusion Criteria:

Risankizumab-Exposed Cohort

  • Exposure to other medications in the same class or as risankizumab (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitor, and other IL-23 inhibitors) at any time during pregnancy (at least 1 dose during pregnancy or prior to pregnancy within a specified time period based on the product's half-life).
  • Occurrence of pregnancy outcome prior to enrollment in the registry

Diseased Comparison Cohort

  • Exposure to risankizumab at any time during pregnancy (at least 1 dose during pregnancy or within 20 weeks prior to conception).
  • Occurrence of pregnancy outcome prior to enrollment in the registry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
818 participants (estimated)

Groups and cohorts

  • Pregnant Women Exposed to Risankizumab

    Pregnant women of any age in the United States (US) who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and exposed to risankizumab at any time during pregnancy.

    Drug: Risankizumab

  • Pregnant Women Not Exposed to Risankizumab

    Pregnant women of any age in the US who are diagnosed with plaque psoriasis, psoriatic arthritis, Crohn's disease, or other conditions for which risankizumab is an FDA-approved treatment and not exposed to risankizumab, but who are exposed to other medications in the same class or line of therapy as risankizumab at any time during pregnancy.

    Drug: Comparator

Interventions

  • Subcutaneous Injection

    Also known as: Skyrizi

  • DrugComparator

    Subcutaneous or Intravenous Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Major Congenital Malformation (MCM)

    MCM is an abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.

    Time frame: Up to 9 months

Secondary outcomes

  1. Number of Participants with Minor Congenital Malformation

    Minor Congenital Malformation is an anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual.

    Time frame: Up to approximately 2 years (1 year post delivery)

  2. Number of Participants with Stillbirth

    Stillbirth is defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary fetal loss occurring at 20 gestational weeks or greater (\>=20 gestational weeks), or, if gestational age is unknown, a fetus weighing 350 g or more (\>=350 g).

    Time frame: Up to 9 months

  3. Number of Participants with Spontaneous Abortion (SAB)

    Spontaneous abortion is defined as an involuntary fetal loss or expulsion of products of conception occurring at less than 20 gestational weeks.

    Time frame: Up to 9 months

  4. Number of Participants with Elective Termination of Pregnancy

    Elective termination of pregnancy is defined as an voluntary fetal loss or interruption of pregnancy, including pregnancy termination that occurs electively.

    Time frame: Up to 9 months

  5. Number of Participants with Preterm Birth

    Preterm birth is defined as live birth occurring at less than 37 gestational weeks.

    Time frame: Up to 9 months

  6. Number of Participants who are Small for Gestational Age (SGA)

    SGA is defined as Birth weight less than the 10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants.

    Time frame: Up to 9 months

  7. Number of Participants with Neonatal Death

    Neonatal death is defined as death of a live-born infant within 28 days of life.

    Time frame: Up to approximately 10 months (one month post delivery)

  8. Number of Participants with Serious Infection in the First 6 Months of Life

    Serious infection is defined as an infection that occurs within an infant's first 6 months of life and results in significant disability, incapacity, or death, is life-threatening, requires inpatient or prolonged hospitalization, or is considered medically important.

    Time frame: Up to approximately 2 years (1 year post delivery)

  9. Number of Participants with Postnatal Growth Deficiency

    Postnatal growth deficiency is defined as postnatal infant weight less than the 10th percentile for sex and chronological age using standard growth charts.

    Time frame: Up to approximately 2 years (1 year post-delivery)

  10. Number of Participants with Infant Developmental Delay

    Infant developmental delay is defined as failure to achieve the developmental milestones for chronological age, as defined by the Center for Disease Control and Prevention (CDC) .

    Time frame: Up to approximately 2 years (1 year post delivery)

07

Study locations

1 of 2 sites recruiting
  • Evidera, a PPD Business Unit /ID# 238688
    Morrisville, North Carolina 27560-7200, United States
    Recruiting
  • PPD Development, LP /ID# 232134
    Wilmington, North Carolina 28401-3331, United States
    Completed

    Not enrolling at this site.

08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jun 2032, 131 months after the start.

Of 52 industry-sponsored observational studies under Arthritis, Psoriatic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 131 months is above that.

Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 15, 2021
StartActual
Jul 30, 2021
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04846959
Lead sponsor
AbbVie
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
Apr 15, 2021
Start date
Jul 30, 2021
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Jul 17, 2025

Study contacts

PPD Inc
Contact
glowpregnancyregistry@ppd.com
1-877-302-2161
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion